SLC5A2 and type 2 diabetes mellitus: A meta-analysis of many cohorts treated with SGLT2 inhibitors [29,30,31] demonstrated that T2DM patients treated with gliflozins had a lower rate of comorbidities (coronary syndrome, heart disease, heart failure, etc.), including a primary composite cardiovascular outcome, and decreased death from any cause when the study drug was added to standard care [32].